← BioTransfer GEO Dataset Finder
GEO series

Blocking IL-4Rα with dupilumab (REGN668/SAR231893) rapidly suppresses major pathomechanisms in the skin of severe atopic dermatitis patients

GSE59294 Homo sapiens Expression profiling by array 40 samples Submitted 2014/12/04 Platform GPL570
Summary
Atopic dermatitis (AD) is the most common inflammatory skin disease, with high unmet need for new therapies that are safe for chronic use. Emerging data suggest that TH2-cytokines play important roles in a variety of allergic and atopic conditions, including asthma and AD. In early phase clinical trials, dupilumab (a fully human monoclonal antibody against IL-4Rα that potently blocks IL-4 and IL-13 signaling) rapidly and markedly improved clinical measures in adults with either asthma (with elevated eosinophil counts) or moderate-to-severe AD. The pathomechanisms that may be impacted by IL-4/13 blockade in these disease settings have not yet been characterized in detail. Transcriptome analyses in pre- and post-treatment skin biopsies from patients with moderate-to-severe AD treated with dupilumab or placebo in two completed clinical trials
This dataset
Download

Direct links to NCBI, no account and no request form: the whole study as GSE59294_RAW.tar, processed values as the series matrix, the supplementary file directory, and per-sample supplementary files for any of the 40 samples.

Also filed as BioProject PRJNA254978. Searching any of these in the dataset finder brings you back here.

Samples in this study

The sample list for this study is not cached yet. Press Sort into groups and it will be fetched from NCBI.

+ 40 more — browse all 40 samples with per-sample file links →

Similar datasets

Search all human microarray datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.